| Revenue Growth | Total revenue $122M, up 80% YoY; Amtagvi $102M; Proleukin $20M. |
|---|---|
| Mgmt Confidence | High confidence in achieving 2026 goals and reaching profitability via growth. |
| Demand Visibility | Over 1,000 commercial patients treated; 100+ Authorized Treatment Centers active. |
| Margin Trends | Record 60% margin in Q3, up from 56% in Q2. |
| Op. Leverage | R&D expenses down 16% sequentially; SG&A held flat despite revenue growth. |
| Pricing Power | High-quality revenue with gross-to-net deductions consistent at approximately 1%. |
| Vol vs Price | Volume-led growth through increased patient infusions and expanded ATC network. |
| Segment Growth | Amtagvi sales grew 77% YoY; Proleukin revenue more than doubled sequentially. |
| New Clients | Added community-based ATCs, now representing over one-third of the network. |
| Capex & Debt | Cash position of $382M expected to fund operations into 2029. |
| Regulatory | Planned 2027 sBLA for lung cancer; Saratoga trial supporting 2028/2029 submissions. |
| Commentary | Focusing on 'precision TIL' strategy using biomarkers to reach 59.1% ORR. |
| New Launches | Expanding into Canada and Australia; UK and Swiss approvals expected Q1 2027. |
Growth
Total revenue grew 80% year-over-year; Amtagvi sales reached $102 million, up 12% sequentially.
Outlook
Reaffirmed 2026 revenue guidance of $410M-$420M; planning lung cancer sBLA submission in 2027.
Risks
Management provided vague timing on mature lung cancer durability data and future profitability milestones.
The company's earnings call, NASDAQ: IOVA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Iovance Biotherapeutics, Inc.: key numbers
- Share price
- $7.55Close, Nov 16
- Market cap
- $3.49B
- Shares outstanding
- 462.66MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Iovance Biotherapeutics, Inc.
All →Iovance Biotherapeutics Investor Presentation
Iovance Biotherapeutics updated its corporate presentation for use at upcoming healthcare conferences and meetings with analysts and stockholders. The November 2026 presentation provides a corporate overview and updates on the company's cell therapy pipeline and commercialization efforts.
Iovance Biotherapeutics Q3 2026 Results: Net Loss of $22.3M, Loss Narrows
Iovance Biotherapeutics reported significant revenue growth for the nine months ended September 30, 2026, reaching $292.2 million compared to $176.7 million in the prior year. The company successfully narrowed its net loss to $148.6 million from $319.1 million, supported by reduced research and development expenses and increased product sales.
- Key figure
- Net loss $22.3M
Iovance Biotherapeutics Financial Results
Iovance Biotherapeutics reported record third quarter 2026 total revenue of approximately $122 million, an 80% increase year-over-year, driven by strong demand for its TIL therapy Amtagvi. The company achieved a record gross margin of approximately 60% and reaffirmed its full-year 2026 revenue guidance of $410 million to $420 million.
- Term
- Q3 2026
“Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand. We remain on track to achieve our full-year 2026 total revenue guidance of $410 to $420 million and recently marked the tremendous milestone of more than 1,000 commercially treated Amtagvi patients.”
Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President
Iovance Biotherapeutics Clinical Trial Data
Iovance Biotherapeutics announced updated Phase 2 IOV-LUN-202 trial results for lifileucel in non-squamous metastatic non-small-cell lung cancer, showing a 24.6% objective response rate in the broader population. A retrospective analysis identified a biomarker-enriched subgroup (KRAS/HER2 wild-type smokers) with a significantly higher 59.1% response rate. The company plans to launch a prospective registrational cohort called POSITILITY in November 2026 and submit a supplemental BLA in 2027.
Iovance Biotherapeutics Investor Presentation
Iovance Biotherapeutics updated its corporate presentation for use at upcoming healthcare conferences and meetings with analysts and stockholders. The presentation provides a corporate overview and strategic update as of October 2026.
Iovance Biotherapeutics Investor Meeting
Iovance Biotherapeutics raised its full-year 2026 total revenue guidance to a range of $410 million to $420 million, up from the previous range of $350 million to $370 million. The increase is driven by strong U.S. demand for its cancer therapies Amtagvi and Proleukin, representing approximately 60% annual growth.